Employer profile
Marksans Pharma
3 certified H-1B filings across 1 fiscal year.
FY2025 filings
3
FY2025 median
$122k
Top role
Senior R&D Lead
2 filings
Top state
NY
3 filings
Marksans Pharma has filed 3 certified H-1B Labor Condition Applications over FY2025. In FY2025, its median certified base salary was $122k ($98k–$200k interquartile range). The most-filed role is Senior R&D Lead (2 filings).
Year-over-year
How Marksans Pharma hired across H-1B fiscal years. YoY column compares to the prior FY.
| FY | Filings | Median $ | YoY % |
|---|---|---|---|
| FY2025 | 3 | $122k | — |
Top job titles
Most-filed positions, across all years (raw DOL titles).
| Job Title | Filings | Median |
|---|---|---|
| Senior R&D Lead | 2 | $98k |
| Vice President - Marketing | 1 | $200k |
Top worksite states
Where this employer files.
| State | Filings | Median |
|---|---|---|
| NY | 3 | $122k |
Prevailing wage level distribution
DOL Levels I–IV approximate experience tiers (I = entry, IV = fully competent). A heavy Level I/II skew suggests entry-level / contractor-style hiring; a heavy IV skew suggests senior in-house roles.
Lvl I
267%
Lvl II
133%
Frequently asked questions
- Does Marksans Pharma sponsor H-1B visas?
- Yes. Marksans Pharma has filed 3 certified H-1B Labor Condition Applications (LCAs) over FY2025. An LCA is a required step before an employer files an H-1B petition; a certified LCA does not by itself guarantee an approved visa.
- What is the median H-1B salary at Marksans Pharma?
- In FY2025, the median certified H-1B base salary at Marksans Pharma was $122k, with a 25th–75th percentile range of $98k–$200k. This is the annual base wage stated on the LCA and excludes bonus, equity, and other compensation.
- What jobs does Marksans Pharma hire H-1B workers for?
- Marksans Pharma's most-filed H-1B role is Senior R&D Lead (2 filings), followed by Vice President - Marketing (1). Its top worksite state is NY.
- How many H-1B filings did Marksans Pharma submit in FY2025?
- Marksans Pharma had 3 certified H-1B LCA filings in FY2025.